# Kohei Shitara

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kohei-shitara/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,314 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 82 |
| i10-index | 329 |
| Last Known Institution | National Cancer Center Hospital East |
| OpenAlex ID | https://openalex.org/A5015799240 |
| ORCID iD | https://orcid.org/0000-0001-5196-3630 |
| Works | 1,143 |

## Researcher papers

- [Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments](https://scholariq.org/papers/lactic-acid-promotes-pd-1-expression-in-regulatory-t-cells-in-highly-glycolytic/)
- [The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies](https://scholariq.org/papers/the-pd-1-expression-balance-between-effector-and-regulatory-t-cells-predicts-the/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer](https://scholariq.org/papers/braf-mutation-is-a-powerful-prognostic-factor-in-advanced-and-recurrent/)
- [Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-with-cisplatin-and-fluoropyrimidine-as-first-line-therapy-in/)
- [Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer](https://scholariq.org/papers/panitumumab-vs-bevacizumab-added-to-standard-first-line-chemotherapy-and-overall/)
- [Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial](https://scholariq.org/papers/primary-tumor-resection-plus-chemotherapy-versus-chemotherapy-alone-for/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gastrointestinal Tumor Research and Treatment](https://scholariq.org/topics/gastrointestinal-tumor-research-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [National Cancer Center Hospital East](https://scholariq.org/institutions/national-cancer-center-hospital-east/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.